The inhalation device maker has secured global rights to develop and commercialise a new ultra-affordable, multi-use blister-based dry powder inhaler patented by Dr Beller
Hovione Technology has secured global rights to develop and commercialise a new ultra-affordable, multi-use blister-based dry powder inhaler patented by inventor Dr Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.
Headquartered in Loughbeg, Northern Ireland, Hovione specialises in inhalation device technology. The company will continue to collaborate with Dr Beller on the inhaler, which will be marketed as the Papillon DPI.
Hovione Technology’s CEO, Peter Villax, said the strategic DPI development for Hovione Technology emphasises the company's long-term commitment to offering a portfolio of innovative inhalers that maximise simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate the commercialization of this innovative blister DPI.
The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at a global scale.
For Hovione Technology, Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.
The inhaler specialist has a co-promotional agreement with active pharmaceutical ingredient manufacturer Hovione and together can provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.
With over 20 years of experience, Hovione Technology’s team has been behind the first market approved disposable dry powder inhaler, the TwinCaps DPI, marketed in Japan for treatment of influenza.